Abstract Library

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,

#3948 Molecular typing and mutational characterisation of rectal neuroendocrine neoplasms

Introduction: Rectal neuroendocrine neoplasms (NENs) are rare neoplasms with limited understanding of its genomic alterations and molecular typing.

Conference:

Presenting Author:

Authors: Duan X, Yin F,

Keywords: rectal neuroendocrine neoplasms, genomic alterations, molecular typing, signaling pathway, DDR mutant genes,

#3910 Integrative molecular analysis of lung neuroendocrine neoplasms with different Ki-67 indices identifies a molecular transition group between low- and high-grade neoplasms

Introduction: In the 2021 World Health Organization (WHO) classification of lung cancers, lung neuroendocrine neoplasms (LNENs) are classified as low-grade, intermediate-grade and high-grade based on mitotic count but not Ki-67 index, as for GEP-NENs.

Conference:

Presenting Author:

Authors: Simbolo M, Centonze G, Ali G, Grillo F, Sabella G,

Keywords: lung neuroendocrine tumor, NET grade 3, next generation sequencing, transcriptomics,

#3760 Comprehensive genomic and transcriptomic analysis of lung carcinoid reveals molecular differences between typical carcinoid and atypical carcinoid

Introduction: Typical carcinoids (TCs) and atypical carcinoids (ACs) are two histotypes of lung carcinoids (LCs) exhibiting different prognoses. However, the diagnosis can be difficult for small biopsies. Moreover, the differences in molecular characteristics of the two subtypes lack understanding.

Conference:

Presenting Author: Guo Y

Authors: Guo Y, Tian C, Cheng Z, Hu S, Chen Q,

Keywords: lung carcinoid, histological subtypes, genomic alteration, transcriptomic difference, drug targets,

#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).

Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Barriuso J, Lamarca A, McNamara M, Manoharan P, Moghadam S,

Keywords: pNETs, WES, everolimus, sunitinib,